No abstract available
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacokinetics*
-
Antineoplastic Agents / therapeutic use
-
Biomarkers / blood
-
Biomarkers / chemistry
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
DNA Adducts / blood
-
DNA Adducts / chemistry
-
Dose-Response Relationship, Drug
-
Half-Life
-
Humans
-
Indazoles / administration & dosage
-
Indazoles / chemistry
-
Indazoles / pharmacokinetics*
-
Indazoles / therapeutic use
-
Infusions, Intravenous
-
Leukocytes / chemistry
-
Metabolic Clearance Rate
-
Neoplasms / drug therapy
-
Neoplasms / metabolism*
-
Organometallic Compounds
-
Ruthenium Compounds / administration & dosage
-
Ruthenium Compounds / chemistry
-
Ruthenium Compounds / pharmacokinetics*
-
Ruthenium Compounds / therapeutic use
-
Serum Albumin / analysis
-
Serum Albumin / chemistry
-
Serum Albumin / metabolism
-
Transferrin / analysis
-
Transferrin / chemistry
-
Transferrin / metabolism
Substances
-
Antineoplastic Agents
-
Biomarkers
-
DNA Adducts
-
Indazoles
-
Organometallic Compounds
-
Ruthenium Compounds
-
Serum Albumin
-
Transferrin
-
indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))